About Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis is a chronic, progressive, and ultimately fatal fibrosing interstitial lung disease of unknown cause, occurring primarily in older adults. Histologically and radiologically characterised by a usual interstitial pneumonia pattern, IPF leads to progressive scarring of lung tissue, worsening dyspnoea, and declining lung function. Two antifibrotic agents, nintedanib and pirfenidone, slow progression but do not reverse the disease.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Idiopathic Pulmonary Fibrosis trials.
Most trials require a confirmed UIP pattern on HRCT or surgical lung biopsy and a minimum FVC (commonly ≥45%) and DLCO (commonly ≥30%); have recent PFTs available.
Current use of nintedanib or pirfenidone may be a criterion or exclusion depending on the study; clarify whether the trial is add-on or treatment-naive.
Acute exacerbations within a defined period (typically 6 months) frequently trigger exclusion; apply during a clinically stable phase.
Patient Resources
Find recruiting Idiopathic Pulmonary Fibrosis trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Idiopathic Pulmonary Fibrosis. Updated daily.